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Introduction {#sec1}
============

Hematopoietic stem cells (HSCs) persist throughout life to produce hematopoietic progenitor cells (HPCs) and all types of blood cells. In the adult, HSCs reside in bone marrow (BM), are rare but have the unique capability for self-renewal and multilineage differentiation ([@bib18]). The maintenance of a steady-state HSC pool adept at dynamic change in response to stress depends on the balance of self-renewal, differentiation, survival, and proliferation ([@bib21]). Loss of this balance could lead to an overexpansion or exhaustion of HSC population, and result in an increased risk for cancer or tissue degeneration. HSCs have been used therapeutically in the clinic for several decades in life-saving treatment of malignant diseases and hematological disorders through BM transplantation protocols ([@bib17]). However, insufficient stem cell numbers significantly limit the efficacy and success of these regimes. Expansion of HSCs while maintaining their self-renewal capability has been one of the most desired, yet elusive, goals in experimental hematology and transplantation medicine ([@bib58]).

HSC fate decisions require strict control. Multiple signaling pathways regulate HSC functions through cell-intrinsic and cell-extrinsic mechanisms ([@bib50], [@bib22]). Genetic manipulation of transcription factors and signal transduction pathways enhances HSC expansion ex vivo ([@bib5], [@bib6]); these include the homeobox gene family ([@bib7]), immobilized Notch ligand ([@bib16]), Wnt-associated prostaglandin E2 ([@bib20]), the soluble growth factors angiopoietin-like 5 ([@bib62]), pleiotrophin ([@bib24], [@bib25]), and miR-126 ([@bib35]), and the aryl hydrocarbon receptor inhibitor ([@bib10]). Moreover, employing an induced pluripotent stem cell population and targeting the HSC microenvironment hold promise for HSC expansion ([@bib9], [@bib34], [@bib27], [@bib13]). However, all these attempts have had limited success clinically, due to a failure to expand sustainable and self-renewable stem cells ([@bib58]).

Our understanding of the molecular pathways for HSC fate decision is insufficient to allow safe manipulation of HSCs for clinical benefit. Large natural variations in HSC number and function exist in humans ([@bib47], [@bib51]) as well as in different mouse strains ([@bib30], [@bib19], [@bib23], [@bib3], [@bib26], [@bib12], [@bib8]). Such natural genetic diversity is an important yet largely unused tool for unraveling the genes and signaling networks associated with stem cell regulation ([@bib57]). Using this genetic diversity tool, we previously identified latexin (*Lxn*) as a stem cell regulatory gene with expression that negatively correlates with HSC number variation in different mouse strains ([@bib15], [@bib40]). *Lxn* is a negative regulator of HSC function and works as a "brake" to constrain the HSC pool to a physiological range. In addition, the canonical function of *Lxn* protein is its inhibitory effect of carboxypeptidase A ([@bib41], [@bib56], [@bib49], [@bib45]). Studies have also shown that LXN has high structural similarity with cystatin and tumor suppressor TIG1 gene, suggesting its potential role in inflammation and transformation ([@bib1]). However, the in vivo function of *Lxn* in hematopoiesis and the underlying regulatory cellular and molecular mechanisms remain largely elusive. Particularly, when drawing upon genetic diversity to identify genes (usually multiple ones) associated with a complex trait (HSC number), all contributing genes are important ([@bib57]). Therefore, it warrants to know to what extent *Lxn* contributes to the natural variation of the size of HSC population and how it specifically regulates HSC function and hematopoiesis.

In this study, we showed that *Lxn* deletion in vivo leads to increased numbers of HSCs, HPCs, and all blood cell lineages. Loss of *Lxn* enhanced long-term repopulating capacity and survival of HSCs. Mechanistically, gene array analysis showed that genes involved in cell-cell and cell-matrix interaction were dysregulated in *Lxn*^−/−^ HSCs, and thrombospondin 1 (*Thbs1*) was identified as a potential downstream target of *Lxn*. *Thbs1* mRNA and protein levels were significantly decreased in *Lxn*^−/−^ HSCs, and ectopic expression of *Thbs1* rescued the *Lxn*^−/−^ HSC phenotype. Our study reveals the cellular and molecular regulatory mechanisms of *Lxn* in HSC homeostasis, and highlights the importance of *Lxn*-mediated intrinsic and extrinsic cellular signaling in the control of HSC function.

Results {#sec2}
=======

*Lxn*^−/−^ Mice Have Increased Blood Cell Numbers and Balanced Lineage Differentiation {#sec2.1}
--------------------------------------------------------------------------------------

The constitutive *Lxn* knockout (*Lxn*^−/−^) mice were generated on the C57BL/6 background. Because Lxn gene lies within the mitochondrial elongation factor G (*Gfm1*) gene, only exons 2 to 4 were targeted for deletion to minimize any potential effect on *Gfm1* ([Figure 1](#fig1){ref-type="fig"}A). Western blot showed complete deletion of the LXN protein in BM, spleen, liver, and brain without affecting GFM1 protein expression ([Figure 1](#fig1){ref-type="fig"}B). Peripheral blood (PB) analysis of *Lxn*^−/−^ mice showed a significant increase in the counts of complete white blood cells, neutrophils, monocytes, lymphocytes, and platelets compared with those of wild-type (WT) mice ([Figure 1](#fig1){ref-type="fig"}C). The percentages of macrophages, granulocytes (Mac-1/Gr-1+), and B lymphocytes (B220+) in *Lxn*^−/−^ mice showed a slight but significant increase ([Figure 1](#fig1){ref-type="fig"}D), whereas the T lineage was not affected (data not shown). These data suggest that *Lxn* deletion increases the number of mature blood cells of both myeloid and lymphoid lineages without skewing differentiation.

*Lxn* Inactivation Leads to Expansion of the HSC and HPC Populations {#sec2.2}
--------------------------------------------------------------------

Analysis of the BM compartment of *Lxn*^−/−^ mice showed a significant increase in cellularity compared with WT mice ([Figure 2](#fig2){ref-type="fig"}A), despite similar body weights (data not shown). Using flow cytometry and immunostaining of HSCs and HPCs ([Figure 2](#fig2){ref-type="fig"}B), we found that the absolute numbers of HPCs, including common myeloid progenitor (CMP), granulocyte/monocyte progenitor (GMP), and common lymphoid progenitor (CLP) cells, were significantly increased in *Lxn*^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}C). Moreover, *Lxn*^−/−^ mice consistently presented a 56% increase in the absolute number of HSC/HPC-enriched LSK cells ([Figure 3](#fig3){ref-type="fig"}D). Among the LSK population, the absolute numbers of long-term (LT)-HSCs, short-term (ST)-HSCs, and multipotent progenitor cells (MPPs) were all significantly increased in *Lxn*^−/−^ mice compared with WT mice ([Figures 2](#fig2){ref-type="fig"}E--2G). These data suggest that *Lxn* inactivation leads to an expansion of the hematopoietic stem and progenitor pool, which contributes to the increased blood cell counts.

*Lxn* Inactivation Increases HSC Clonogenic and Repopulating Capacity in a Cell-Intrinsic Manner {#sec2.3}
------------------------------------------------------------------------------------------------

To define the effect of *Lxn* inactivation on the function of HSCs and HPCs, we used the in vitro culture system, including cobblestone area-forming cell (CAFC) and colony-forming cell (CFC) assays, to assess the clonogenic potential of HSCs and HPCs, respectively. [Figure 3](#fig3){ref-type="fig"}A shows that the number of primitive HSCs (CAFC day 35) was 3-fold higher in *Lxn*^−/−^ BM than WT BM. Moreover, the total number of CFCs generated by *Lxn*^−/−^ BM cells was increased by nearly 2-fold compared with WT cells ([Figure 3](#fig3){ref-type="fig"}B). We next evaluated the capability of *Lxn*^−/−^ HSCs to reconstitute the hematopoiesis of myeloablated mice by a competitive repopulation assay ([Figure 3](#fig3){ref-type="fig"}C). The results showed that *Lxn*^−/−^ HSCs made a greater contribution to the repopulation of PB leukocytes at both 8 weeks and 16 weeks post transplantation compared with WT cells ([Figure 3](#fig3){ref-type="fig"}D). Analysis of PB lineage chimerism at 16 weeks showed that the engrafted *Lxn*^−/−^ HSCs retained multilineage differentiation potential and contributed to more circulating myeloid and B cells than the WT cells ([Figure 3](#fig3){ref-type="fig"}E). This recapitulates the intrinsic changes of *Lxn*^−/−^ cells in physiological condition ([Figure 1](#fig1){ref-type="fig"}D). Analysis of BM chimerism showed that mice transplanted with *Lxn*^−/−^ cells presented with 66.4% (±9.9%) donor-derived cells, whereas in mice receiving WT cells, the contribution was dramatically lower at 30.9% (±16.9%) ([Figure 3](#fig3){ref-type="fig"}F). In the BM LSK compartment, the percentage and absolute number of *Lxn*^−/−^-derived LSK cells was nearly 3-fold higher than that of WT-derived cells ([Figures 3](#fig3){ref-type="fig"}G and 3H, respectively). Altogether, these results reinforce findings of increased numbers of functional HSC and HPC, as measured by their clonogenic activity in *Lxn*^−/−^ mice. The data suggest that *Lxn* inactivation significantly enhances HSC long-term reconstitution capacity and maintains multilineage differentiation potential in a cell-intrinsic manner. Moreover, the extent of expansion of *Lxn*^−/−^-derived LSK population in this transplantation setting (3-fold) is higher than that in in situ condition (1-fold, [Figure 2](#fig2){ref-type="fig"}D), indicating the likelihood of increased self-renewal of *Lxn*^−/−^ HSCs. Future studies are needed to address this by the serial transplantability of *Lxn*^−/−^ HSCs.

*Lxn* Inactivation Enhances HSC Survival without Affecting Cell Cycling {#sec2.4}
-----------------------------------------------------------------------

The HSC pool size is maintained by the balance of apoptosis and proliferation. Apoptosis analysis with Annexin V showed that the percentage of Annexin V+ propidium iodide-negative (PI--) apoptotic cells ([Figure 4](#fig4){ref-type="fig"}A) was significantly decreased by nearly 50% in *Lxn*^−/−^ LSK cells, and subsets of HSCs (LT-HSCs, ST-HSCs, and MPPs) compared with the WT cells ([Figure 4](#fig4){ref-type="fig"}B). Increased survival was further confirmed by flow cytometric analysis of LSK cells positive for active caspase-3 ([Figure 4](#fig4){ref-type="fig"}C). The percentage of positive cells was significantly lower in *Lxn*^−/−^ mice than that in WT mice ([Figure 4](#fig4){ref-type="fig"}D). Moreover, expression of active caspase-3, as measured by the mean fluorescence intensity, was lower in *Lxn*^−/−^ LSK cells than in WT cells ([Figure 4](#fig4){ref-type="fig"}E). These data suggest that *Lxn* inactivation can intrinsically enhance HSC survival. We further followed the response of WT and *Lxn*^−/−^ HSCs to 5-fluorouracil (5-FU)-induced hematopoietic stress, and found that LSK cells in *Lxn*^−/−^ BM recovered faster than that in WT mice ([Figure 4](#fig4){ref-type="fig"}F), and less *Lxn*^−/−^ LSK cells underwent apoptosis ([Figure 4](#fig4){ref-type="fig"}G). These results indicate that *Lxn* deletion protects hematopoietic stem/progenitor cells from 5FU-induced myelosuppression by enhancing their survival.

We next examined the cell-cycle status with Ki-67/PI staining and bromodeoxyuridine (BrdU) incorporation, and did not observe any significant difference in cell-cycle distribution and cycling dynamics between *Lxn*^−/−^ and WT LT-HSCs ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B, respectively). This result suggests that *Lxn* did not affect stem cell cycling under physiological conditions.

*Lxn*^−/−^ Mice Do Not Develop Hematological Malignancy during Aging {#sec2.5}
--------------------------------------------------------------------

We and others have shown that *Lxn* is downregulated in leukemia, lymphoma, and several other cancers ([@bib37], [@bib42], [@bib44], [@bib2], [@bib46], [@bib48]). Since young *Lxn*^−/−^ mice did not show any obvious sign of hematological malignancy, we asked whether aging could promote tumor development in *Lxn*^−/−^ mice. Cohorts of *Lxn*^−/−^ and WT mice were physiologically aged for 28 months and the hematopoietic profile in PB and BM was analyzed. No significant difference in either complete or differentiated blood cell counts was identified between aged-matched *Lxn*^−/−^ and WT mice ([Figure 5](#fig5){ref-type="fig"}A). Lineage differentiation in old *Lxn*^−/−^ mice showed a slight but significant increase in myeloid lineage and decrease in B lymphocytes ([Figure 5](#fig5){ref-type="fig"}B), although both strains demonstrated age-associated myeloid skewing and immunodeficiency compared with their young counterparts ([Figure 1](#fig1){ref-type="fig"}D). No significant difference was found in BM cellularity ([Figure 5](#fig5){ref-type="fig"}C) and the number of CFCs ([Figure 5](#fig5){ref-type="fig"}D). Aged *Lxn*^−/−^ mice had nearly 2-fold more LT-HSCs in both frequency and absolute numbers than age-matched WT counterparts, but no significant difference was observed in other HSC sub-populations ([Figures 5](#fig5){ref-type="fig"}E and 5F). Importantly, the overall health of old *Lxn*^−/−^ mice was comparable with the controls, and no apparent pathological changes were detected in blood, BM, spleen, and liver of *Lxn*^−/−^ mice (data not shown). These data suggest that *Lxn*^−/−^ mice are not inherently prone to hematological malignancy.

*Thbs1* Is a Downstream Target of *Lxn* {#sec2.6}
---------------------------------------

We performed gene array analysis in phenotypically defined LT-HSCs and MPPs, respectively, to determine *Lxn* inactivation-induced molecular changes. A total of 3,561 genes are differentially expressed, among them one-third (1,235) are upregulated and two-thirds (2,326) are downregulated. Gene set enrichment analysis (GSEA) showed alteration in six signaling pathways enriched in *Lxn*^−/−^ cells, and three of them involved cell-cell and cell-extracellular matrix interaction ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Among the top ten up- and downregulated genes ([Figure S2](#mmc1){ref-type="supplementary-material"}B), *Thbs1* is one of the most interesting candidates. The rationale is that *Thbs1* is a multidomain matrix glycoprotein that interacts with numerous adhesion receptors and proteases, and mediates cell-cell and cell-matrix interactions ([@bib4]). *Thbs1* has been shown to enhance cell survival and regulate hematopoietic progenitor recovery under stress conditions ([@bib28]). These functions are consistent with the functional effects of *Lxn* ([@bib60]), which prompted us to further investigate whether *Thbs1* is the downstream target of *Lxn*. Our microarray data showed a significant decrease in *Thbs1* expression in *Lxn*^−/−^ HSCs. Quantitative real-time PCR validated the downregulation of *Thbs1*; a reduction in mRNA expression of at least 2-fold was identified in different subsets of *Lxn*^−/−^ HSCs ([Figure 6](#fig6){ref-type="fig"}A). It is noteworthy that the expression level of *Thbs1* increased with the content of primitive hematopoietic cells, reaching the highest in the most primitive HSC population. Such expression pattern is similar to that of *Lxn*, as we reported previously ([@bib40]), further corroborating the association between *Thbs1* and *Lxn*. THBS1 protein, measured by western blot, also decreased in *Lxn*^−/−^ HSC/HPC-enriched Lin-- cKi+ cells ([Figure 6](#fig6){ref-type="fig"}B, left). THBS1 is a secreted protein ([@bib4]). We therefore measured its level in BM fluid and found that *Thbs1* content in the *Lxn*^−/−^ BM microenvironment was also reduced ([Figure 6](#fig6){ref-type="fig"}B, right). Immunofluorescence staining of THBS1 protein level in BM sections of *Lxn*^−/−^ mice confirmed reduced protein content of THBS1 ([Figure 6](#fig6){ref-type="fig"}C). Furthermore, [Figure 6](#fig6){ref-type="fig"}D shows that the THBS1 protein content was reduced in individual *Lxn*^−/−^ LSK cells compared with WT ones (left), and the percentage of *Thbs1*+ LSK cells was significantly decreased in *Lxn*^−/−^ BM cells compared with that in WT cells (right).

To further confirm the positive correlation between *Lxn* and *Thbs1* expression, we overexpressed *Lxn* in WT LSK cells, and found that *Thbs1* mRNA level was significantly increased ([Figure S3](#mmc1){ref-type="supplementary-material"}). Moreover, we analyzed BM HSCs in *Thbs1*^+/−^ mice in which THBS1 protein was decreased ([Figure 6](#fig6){ref-type="fig"}E), and found that the number of LSK cells and CAFC day 35 cells was significantly higher in *Thbs1*^+/−^ BM than those in WT BM cells ([Figures 6](#fig6){ref-type="fig"}F and 6G), a phenotype similar to *Lxn*^−/−^ mice ([Figures 2](#fig2){ref-type="fig"}D and [3](#fig3){ref-type="fig"}A). These data strongly suggest that *Thbs1* is a downstream target of *Lxn*.

*Thbs1* is a natural inhibitor of angiogenesis, megakaryopoiesis, and thrombopoiesis ([@bib4]), all of which have been shown as critical niche components implicated in HSC regulation ([@bib31], [@bib52], [@bib11], [@bib61]), We asked whether the reduced *Thbs1* levels in *Lxn*^−/−^ HSCs and surrounding environment could affect these niche components. There was no significant difference in the number of megakaryocytes and megakaryocyte progenitor cells in *Lxn*^−/−^ mice ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B, respectively) compared with WT mice. No difference in the expression of von Willebrand factor and CD41, two megakaryocyte markers, was shown in the microarray of *Lxn*^−/−^ cells (data not shown). Moreover, the number of endothelial cells and the function of platelets also remain unchanged in *Lxn*^−/−^ mice ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D, respectively). Altogether, these data suggest that *Thbs1* is a specific downstream target of *Lxn*, and the decreased level of Thbs1 might affect *Lxn*^−/−^ HSCs in a cell-intrinsic manner.

Enforced Expression of *Thbs1* Reverts the *Lxn*^−/−^ HSC Phenotype {#sec2.7}
-------------------------------------------------------------------

To directly address the involvement of *Thbs1* in the HSC phenotype of *Lxn*^−/−^ mice, we overexpressed *Thbs1* in WT and Lxn^−/−^ LSK cells ([Figures 7](#fig7){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}). Quantitative real-time PCR and western blot analysis confirmed increased expression of *Thbs1* at both transcript and protein levels in *Lxn*^−/−^ cells transduced with a *Thbs1* virus compared with cells transduced with empty vector ([Figures 7](#fig7){ref-type="fig"}B and 7C, respectively). [Figure 7](#fig7){ref-type="fig"}D showed that *Thbs1* overexpression dramatically reduced the number of *Lxn*^−/−^ HSCs assessed by CAFC at day 35. Moreover, when *Thbs1*-overexpressing *Lxn*^−/−^ stem cells were transplanted into myeloablated recipients, they showed a significant lower capacity to reconstitute recipients\' PB than control *Lxn*^−/−^ cells at 16 weeks post transplantation ([Figure 7](#fig7){ref-type="fig"}E). Consistently, *Thbs1* overexpression reduced the BM LSK cell reconstitution by nearly 2-fold ([Figure 7](#fig7){ref-type="fig"}F), which reverted the increased repopulation capacity seen in *Lxn*^−/−^ HSCs ([Figures 3](#fig3){ref-type="fig"}D and 3G). However, we did not see any significant change in CAFC day 35 number in *Thbs1*-overexpressing WT cells, suggesting *Thbs1* as a specific downstream target of *Lxn* ([Figure S5](#mmc1){ref-type="supplementary-material"}). Overall, the data indicate that enforced *Thbs1* expression can revert the *Lxn*^−/−^ phenotype, suggesting that the functional effect of *Lxn* may act, in part, through *Thbs1*.

Discussion {#sec3}
==========

*Lxn* was originally identified by the natural variation of HSC numbers between C57BL/6 and DBA/2 mice, in which the C57BL/6 strain had a lower HSC number than the DBA/2 strain ([@bib40]). *Lxn* expression negatively correlates with this variation, that is, its expression is higher in C57BL/6 HSCs than DBA/2 stem cells. However, the specific role of *Lxn* in hematopoiesis remains largely unknown.

In this study, we determined the in vivo function of *Lxn* in regulating HSC function and maintaining homeostatic hematopoiesis, and uncovered the cellular and molecular mechanisms that control these processes. Using the *Lxn* knockout mouse model generated on the C57BL/6 background, we found that loss of *Lxn* in vivo led to an expansion of the entire hematopoietic hierarchy, from the stem cell pool to the PB cells. Very interestingly, the increased number of HSCs in *Lxn*^−/−^ mice is comparable with that of the DBA/2 strain ([@bib40]), suggesting that *Lxn*, as the natural regulator, has the unique characteristic of maintaining the physiologic range of the HSC pool size. Therefore, reduction or even deletion of *Lxn* activity results in a controlled expansion of HSCs without impairment of stem cell repopulating and multilineage differentiation capacity. Indeed, the transplantation studies show that *Lxn*^−/−^ HSCs have a much better long-term repopulation capacity with a balanced output of blood cells. Moreover, controlled expansion reduces the risk of malignant hyperplasia, supported by the observation that *Lxn*^−/−^ mice did not spontaneously develop hematologic malignancy even during aging. Altogether, antagonism of *Lxn* function may have a therapeutic potential through a controlled expansion of HSCs without exhaustion or transformation.

The molecular mechanisms by which *Lxn* regulates HSC function remain largely unknown. Here, we provide strong evidence to support Thbs1 as a downstream target that mediates control of HSC by *Lxn*: (1) loss of *Lxn* dramatically decreased *Thbs1* mRNA and protein levels; (2) ectopic expression of *Lxn* significantly increased *Thbs1* transcript level; (3) *Thbs1*^+/−^ mice phenocopied *Lxn*^−/−^ mice in their BM HSC population by showing an enlarged HSC pool; and (4) ectopic expression of *Thbs1* reverted the *Lxn*^−/−^ HSC phenotype. *Thbs1* is a multidomain adhesive glycoprotein that mediates cell-cell and cell-matrix interactions ([@bib4]). It interacts with a wide range of cell adhesion receptors and numerous proteases, and is involved in various cellular processes, such as inhibition of angiogenesis, megakaryocytopoiesis, and platelet function ([@bib59], [@bib32], [@bib29]). However, our results indicate that decreased expression and secretion of *Thbs*1 in *Lxn*^−/−^ HSCs and surrounding environment does not alter these niche cellular components; Since *Thbs1* is a matrix protein, one of the regulatory mechanisms of *Lxn* may involve cell-cell and/or cell-niche interactions by altering the abundance of matrix proteins ([Figure 7](#fig7){ref-type="fig"}G). This discovery is consistent with a previous report from the Furukawa group, although they identified different adhesion molecules: N-cadherin, *Tie2*, and Roundabout 4 ([@bib44]). This discrepancy may be due to the reasons that they used a less primitive cell population (SCA-1+) for proteomic analysis and/or they deleted the entire *Lxn* gene in the knockout mouse model. Nevertheless, additional investigations on the role of *Lxn* in stem cell trafficking, including mobilization and homing would be valuable.

*Thbs1* can induce apoptosis via upregulation of active caspase-3 ([@bib36]). Consistently, *Lxn*^−/−^ HSCs demonstrated decreased apoptosis and reduced levels of active caspase-3, suggesting that downregulation of *Thbs1* might also intrinsically enhance *Lxn*^−/−^ stem cell survival ([Figure 7](#fig7){ref-type="fig"}G). An increased survival could boost stem cell tolerance to genotoxic or cytotoxic stress. Indeed, absence of *Thbs1* confers near complete resistance to injury from high-dose radiation, partly through mitigation of radiation-induced BM cell apoptosis ([@bib28], [@bib54]). Moreover, *Thbs1* knockout mice demonstrated an accelerated hematopoietic recovery following 5-FU-induced myelosuppression ([@bib33]). Interestingly, our published work has shown that *Lxn* is involved in radiation response and it increases the radiation sensitivity of myeloid progenitor cells ([@bib60]). Therefore, we speculate that loss of *Lxn* may protect HSCs from radiation- and/or chemotherapy-induced myelosuppression and long-term damages. We indeed showed that *Lxn*^−/−^ mice had a much faster recovery in hematopoietic stem/progenitor cells from 5-FU-induced stress.

HSCs have served as a fundamental model for the study of stem cell biology and as a vital therapeutic modality for the treatment of hematopoietic malignancies and BM failure syndromes ([@bib14], [@bib17]). Our results show that inhibition of *Lxn* activity leads to the controlled expansion of HSC population without impairment of self-renewal capacity and induction of malignant hyperplasia. Therefore, *Lxn* might be a promising genetic target for HSC expansion. More importantly, since *Lxn* was identified by the genetic diversity underlying HSC natural variations, it is highly likely that *Lxn* may function similarly in humans and manipulation of *Lxn* activity could provide translational impact ([@bib57], [@bib17]).

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

C57BL/6 mice and B6.SJL/BoyJ (CD45.1) recipient mice were purchased from The Jackson Laboratory. Latexin constitutive knockout mice (*Lxn*^−/−^) were generated by TaconicArtemis. *Thbs1* heterozygous knockout mice (*Thbs1*^+/−^) were kindly provided by Dr. Shuxia Wang ([@bib38], [@bib43]). All mice used were 8--12 weeks old. Mice were housed in the University of Kentucky animal facilities following NIH-mandated guidelines for animal welfare and with IACUC approval. Complete blood count was performed on a Hemavet 950 (Drew Scientific). 5-FU was intraperitoneally injected at a concentration of 100 mg/kg body weight.

Immunostaining and Flow Cytometry {#sec4.2}
---------------------------------

HSCs, HPCs, and stromal cells: BM cells were stained with lineage antibodies, including CD5 (clone 53--7.3), CD8a (clone 53--6.7), CD45R/B220 (clone RA3-6B2), CD11b/MAC-1 (clone M1/70), LY-6G/GR-1 (clone RB6-8C5), and TER119/Ly-76 (clone TER-119)-APC-Cy7, and stem cell markers, C-KIT-APC, SCA-1-PE-Cy5.5, CD34-FITC, and FLT3-PE. HPCs were stained with FcγR and IL7R. HSC/HPC-enriched LSK cells, LT-HCSs and ST-HSCs, MPPs, and HPCs, including CMP, GMP, megakaryocyte/erythroid progenitor (MEP) and CLP cells were immunophenotypically defined as different markers. BM megakaryocytes and endothelial cells were stained with CD41 (clone MWR/REG30) and CD31 (clone MEC13.3), respectively. Dead cells were excluded by PI selection. PB lineage chimerism staining was stained with CD45.2 and CD45.1 markers and MAC-1/GR1, THY1, and B220 markers. Cell-cycle analysis was performed using Ki-67 and 7-aminoactinomycin D (7-AAD) staining. In vivo BrdU incorporation was used to study cell-cycle dynamics. BrdU was administered in drinking water (0.5 mg/mL) for 3 days and the percentage of BrdU+ LT-HSCs was analyzed daily. Apoptosis was performed with Annexin V and 7-AAD. Antibodies were purchased from eBioscience, BioLegend, or BD Pharmingen. Negative controls for fluorescence-activated cell sorting (FACS) gating was set by cells without any antibody staining. Flow cytometry was performed on a FACSAria II (Becton Dickinson) and the data were analyzed using FlowJo software (TreeStar).

In Vitro Colony Assays {#sec4.3}
----------------------

\(1\) CFC assay was performed as described previously in complete MethoCult medium (STEMCELL Technologies), Colony formation was observed on days 7 and 14 ([@bib39]). (2) CAFC assay was performed as described previously ([@bib40]). The most primitive HSCs showed cobblestones at day 35, whereas HPCs show colonies at early dates, such as CAFC day 7. CAFC frequencies were calculated by using L-CaLc limiting dilution analysis software (STEMCELL Technologies).

BM Transplantation {#sec4.4}
------------------

In competitive repopulation assays, 1 × 10^6^ donor cells from *Lxn*^−/−^ or WT BM (CD45.2) mice were mixed with an equal number of competitor BM cells (B6.SJL/BoyJ) and retro-orbitally injected into lethally irradiated (9 Gy) recipient mice. For transplantation of *Thbs1*-overexpressing *Lxn*^−/−^ cells, sorted 1 × 10^5^ GFP+ cells that were either *Thbs-1* overexpression or empty vector control *Lxn*^−/−^ BM cells were mixed with 2 × 10^5^ competitor cells, and injected into B6.SJL/BoyJ recipient mice. Percentages of donor (CD45.2 or GFP+)-derived PB and BM cells were determined at 16 weeks post transplantation ([@bib40]).

Microarray Analysis {#sec4.5}
-------------------

Microarray was performed on LT-HSCs and MPPs in the Microarray Facility Center at the University of Kentucky. In brief, nearly 100,000 LT-HSCs and MPPs were sorted from pooled marrows of 10--20 WT or Lxn^−/−^ mice. Total RNA was extracted using RNeasy Kit (QIAGEN) and processed onto the Affymetrix Gene Chip MoGene-1_0-st-v1 Arrays. Three independent samples were obtained from each strain. Microarray data were normalized by the robust multiarray averaging method. The limma package ([@bib53]) in R/Bioconductor was used to determine the differentially expressed genes. In GSEA ([@bib55]) ([www.broadinstitute.org/gsea/index.jsp](http://www.broadinstitute.org/gsea/index.jsp){#intref0010}), genes were preranked based on the absolute values of their limma test statistics. Pathways in the Kyoto Encyclopedia of Genes and Genomes database were investigated. Enriched pathways were identified with false discovery rate less than 0.2.

mRNA and Protein Quantification {#sec4.6}
-------------------------------

Quantitative real-time PCR was performed as described previously ([@bib40]) with a commercially available primer/probe mix for *Thbs1* in ABI PRISM 7700 (Applied Biosystems). Western blot was performed as described previously ([@bib40]). Antibodies were anti-GFM-1 (Abcam), anti-THBS-1 (Cell Signaling Technology), anti-LXN, and anti-Actin (Sigma).

Overexpression of *Thbs-1* in BM Cells {#sec4.7}
--------------------------------------

Flow cytometry sorted LSK cells from C57/BL6 or *Lxn*^−/−^ mice were stimulated with cytokines including 100 ng/mL FMS-like tyrosine kinase-3 ligand, 50 ng/mL mouse stem cell factor, 10 ng/mL interleukin-3 (IL-3), and 10 ng/mL IL-6 in StemSpan SFEM (STEMCELL Technologies). After 24 hr, the cells were transduced with lentiviral particles encoding either m*Thbs1* (catalog no. EX-Mm05712-Lv165), m*Lxn* (catalog no. EX-Mm03695-Lv165), or its related empty vector (catalog no. EX-NEG-Lv165), at an MOI of 100 for 6 hr at 37°C. All lentiviral particles were premade and purchased from GeneCopoeia. After 48 hr, the GFP-positive cells were sorted for real-time PCR, western blotting, CAFC assay, and transplantation assays. In transplantation assay, 1 × 10^5^ GFP+ cells plus 2 × 10^5^ competitor B6.SJL/BoyJ BM cells were injected into B6.SJL/BoyJ mice, and GFP+ chimerism in PB and BM was measured at 16 weeks post transplantation. The CAFC assay of GFP+ cells was as described above.

Statistical Analysis {#sec4.8}
--------------------

Data were examined for homogeneity of variances (F test), then analyzed by Welch\'s t test or one-way ANOVA with post hoc analysis by Tukey\'s test. Differences were considered significant at p \< 0.05. All statistical analyses were conducted using SPSS 16.0 for Windows.
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![*Lxn* Inactivation Increases Peripheral Blood Cell Numbers\
(A) Scheme representing the *Lxn* gene targeting strategy. The *Lxn* gene lies within the *Gfm-1* gene and only exons 2 to 4 of the *Lxn* gene were removed to minimize any potential effect on the *Gfm-1* gene.\
(B) Western blot analysis of *Lxn* and *Gfm-1* protein from the indicated organs of *Lxn*^−/−^ and WT control mice.\
(C) Differential blood cell counts of *Lxn*^−/−^ and WT mice. Statistically significant differences are: ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01.\
(D) Lineage differentiation analysis by immunostaining and flow cytometry of *Lxn*^−/−^ and WT myeloid cells (MAC1/GR1+) and B lymphocytes (B220+). ^∗^p \< 0.01. Presented data in (C and D) are the mean ± SD from three independent experiments (n = 22 in *Lxn*^−/−^, n = 20 in WT mice).](gr1){#fig1}

![*Lxn* Inactivation Expands the Immunophenotypically Defined HSCs and HPCs\
(A) Total femoral BM cell counts (cellularity) of *Lxn*^−/−^ (n = 22) and WT (n = 20) mice. ^∗∗^p = 0.002.\
(B) Representative FACS plots for HSC and HPC cell populations, including HSC and HPC-enriched LSK cells, HSC subsets (LT-HSCs, ST-HSCs, and MPPs), myeloid committed progenitor cells (CMPs, GMPs, and MEPs), and common lymphoid progenitor cells (CLPs). Cell surface makers for identification of each cell populations are indicated.\
(C) Absolute number of CMPs (^∗^p = 0.03), GMPs (^∗^p = 0.02), MEPs, and CLPs (^∗^p = 0.04) in one femur of an *Lxn*^−/−^ and a WT mouse.\
(D) Absolute number of LSK cells in one femur of an *Lxn*^−/−^ and a WT mouse. ^∗^p = 0.046.\
(E--G) Absolute number of LT-HSCs (^∗∗^p = 0.003), ST-HSCs (^∗^p = 0.02), and MPP cells (^∗^p = 0.048) in one femur of an Lxn^−/−^ and a WT mouse.\
Presented data in (A--G) are the average ± SD pooled from three independent experiments with three mice per experiment for both strains (n = 9 each strain).](gr2){#fig2}

![*Lxn* Inactivation Increases the Number of Functional HSCs and HPCs, and Enhances the Competitive Repopulation Capacity of HSCs\
(A) Absolute number of clones, defined by the cobblestone area-forming cell (CAFC) assay, at d35 of culture for HSC cells from *Lxn*^−/−^ and WT mice (^∗∗∗^p = 0.0002).\
(B) Absolute number of clones, defined by colony-forming cell (CFC) assay, at day 14 of culture for HPC cells from *Lxn*^−/−^ and WT mice (^∗^p = 0.01). Presented data are the average ±SD pooled from three independent experiments with three mice per experiment for both strains (n = 9 each strain).\
(C) Experimental scheme for competitive repopulation assay.\
(D--H) Frequencies of *Lxn*^−/−^ or WT donor (CD45.2)-derived leukocytes at 4, 8, and 16 (^∗∗∗^p \< 0.001) weeks after transplantation in the PB of recipient mice (CD45.1). At 16 weeks after transplantation in the BM of recipient mice, frequencies of *Lxn*^−/−^ or WT donor (CD45.2)-derived (E) myeloid cells (M/G; ^∗^p = 0.02), T and B lymphocytes (^∗∗∗^p \< 0.001), (F) BM nucleated (^∗∗∗^p \< 0.001), and (G) LSK cells (^∗∗∗^p \< 0.001), as well as (H) absolute numbers of LSK cells in one femur (^∗∗∗^p \< 0.001), were measured.\
Presented data in (D--H) are the average ± SD pooled from two independent experiments with five recipients receiving either *Lxn*^−/−^ or WT BM cells per experiment (n = 10 per donor group).](gr3){#fig3}

![*Lxn*^−/−^ HSCs have Increased Survival\
(A) Representative FACS plots of Annexin V+ and 7-AAD apoptotic LT-HSCs (left plots). Thymocytes were used as control to determine the Annexin V+ population, as we published previously ([@bib40]).\
(B) Percentage of apoptotic cells in populations of LSK cells, MPPs, ST-HSCs, and LT-HSCs of *Lxn*^−/−^ and WT mice. Presented data are the average ± SD of five mice/group.\
(C) Representative flow cytometry profile of active caspase-3 immunofluorescence signal in LSK cells.\
(D) Frequency of LSK cells positive for active caspase-3 (^∗^p = 0.04).\
(E) The level of the active caspase-3 protein in LSK cells of WT and Lxn^−/−^ mice. Shown is the histogram of active caspase-3 protein in flow cytometry analysis. Data were the average of three independent experiments with three mice in each one (n = 9).\
(F) *Lxn*^−/−^ mice had a faster recovery in LSK cells after 5-FU-induced hematopoietic stress at days 1, 3, 6, 10, and 14.\
(G) Less *Lxn*^−/−^ LSK cells underwent apoptosis at 24 hr after 5-FU injection.\
Data were the average of five mice at each time point in each group. ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, and ^∗^p \< 0.05.](gr4){#fig4}

![Aged *Lxn*^−/−^ Mice Do Not Spontaneously Develop Hematologic Malignancy\
In age-matched old *Lxn*^−/−^ and WT mice, the following hematopoietic phenotypes were measured.\
(A) Differential blood cell counts.\
(B) Lineage differentiation analysis of myeloid cells (M/G; ^∗^p = 0.02) and T and B lymphocytes (^∗^p = 0.03).\
(C) Total BM cell counts (cellularity).\
(D) Absolute number of CFC progenitor cell clones on day 14 of culture.\
(E) Frequency of LSK cells, LT-HSCs (^∗^p = 0.02), ST-HSCs, and MPPs in one femur.\
(F) Absolute number of LSK cells, LT-HSCs (^∗^p = 0.02), ST-HSCs, and MPPs in one femur.\
Presented data in (A--F) are the average ± SD pooled from *Lxn*^−/−^ (n = 15) and WT (n = 19) mice.](gr5){#fig5}

![*Thbs1* Is the Downstream Target of *Lxn*\
(A) Real-time PCR data demonstrating *Thbs1* mRNA levels in LSK, MPP, and HSCs. ^∗∗^p \< 0.01 and ^∗^p \< 0.05. HSCs are the combination of both LT-HSC and ST-HSCs (Lin-- Sca1+ c-Kit+ Flt3 cells). Presented data are the average ±1 SD of 12 measurements derived from three separate samples.\
(B) Western blot analysis of *Thbs1* protein in BM LIN-C-KIT+ (LK) cells and BM fluid. Actin (ACT) was normalization control. Blots are representative of three independent experiments.\
(C) Immunofluorescence staining of the *Thbs1* protein (red) in BM sections from *Lxn*^−/−^ and WT mice. Scale bars, 50 μm.\
(D) Immunofluorescence staining of *Thbs1* protein (green) in individual *Lxn*^−/−^ or WT LSK cells (left panel) and quantification of LSK cells positive for *Thbs1* staining (right panel). All cells (50--100) in the field were captured and analyzed in each sample. Scale bars, 5 μM. ^∗∗∗^p = 0.0003.\
(E) *Thbs1* heterozygous knockout mice (*Thbs1*^+/−^) had reduced THBS1 levels. Western blot was performed on LSK cells and shown is one representative blot of two replicates.\
(F) Increased number of LSK cells in *Thbs1*^+/−^ BM. BM cells from *Thbs1*^+/−^ mice were flow cytometrically analyzed for the LSK population. Data shown are the mean ±1 SD. ^∗∗^p = 0.01.\
(G) Increased number of long-term colony-forming cells (CAFC day 35) in *Thbs1*^+/−^ BM. Data shown are the mean ±1 SD. ^∗∗∗^p = 0.003.](gr6){#fig6}

![Overexpression *Thbs1* Rescues *Lxn*^−/−^ Hematopoietic Phenotype\
(A) Experimental scheme for lentivirus-mediated *Thbs1* overexpression strategy in LSK cells.\
(B and C) Quantitative real-time PCR (B) and western blot analysis (C) of *Thbs1* mRNA and protein, respectively, in *Thbs1*-overexpressing (*Thbs1*) *Lxn*^−/−^ LSK cells. Actin (ACT) was normalization control (Con). Blots are representative of two independent experiments. ^∗∗∗^p \< 0.001.\
(D) Absolute number of HSC clones, defined by CAFC day 35 in *Thbs1*-overexpressing (*Thbs1*) *Lxn*^−/−^ LSK cells. ^∗∗∗^p \< 0.001.\
(E) Frequencies of *Thbs1*-overexpressing (*Thbs1*) or control *Lxn*^−/−^ donor cells from (GFP+)-derived PB leukocytes in recipient mice. ^∗^p = 0.04.\
(F) Absolute number of BM LSK cells, repopulated by *Thbs1* overexpression (*Thbs1*), or in control *Lxn*^−/−^ donor cells (GFP+) from transplantation recipient mice. ^∗∗^p = 0.009. Presented data in (C--F) are the average ± SD pooled from two independent experiments with five recipients receiving GFP+ cells per experiment (n = 10 per donor group).\
(G) Model of regulation of HSC function by the *Lxn-Thbs1* pathway. Deletion of the HSC regulatory gene, *Lxn*, causes downregulation of *Thbs1* mRNA and protein in stem cells, which may lead to the decreased level of active caspase-3. As a result, *Lxn*^−/−^ HSCs have an enhanced survival. Decreased level of *Thbs1* in the BM environment may affect HSC-niche interaction, which may lead to the increased repopulating capacity of HSCs. Increased survival and function may contribute to the expansion of HSC pool.](gr7){#fig7}
